pentadecapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-03. Anything still debated is marked as such rather than presented as settled.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
=== Other functions === EF-Tu has been found in large quantities in the cytoskeletons of bacteria, co-localizing underneath the cell membrane with MreB, a cytoskeletal element that maintains cell shape. Defects in EF-Tu have been shown to result in defects in bacterial morphology. Additionally, EF-Tu has displayed some chaperone-like characteristics, with some experimental evidence suggesting that it promotes the refolding of a number of denatured proteins in vitro. EF-Tu has been found to moonlight on the cell surface of the pathogenic bacteria Staphylococcus aureus, Mycoplasma pneumoniae, and Mycoplasma hyopneumoniae, where EF-Tu is processed and can bind to a range of host molecules. In Bacillus cereus, EF-Tu also moonlights on the surface, where it acts as an environmental sensor and binds to substance P.
=== Fictional character biography === James Howlett was born near Cold Lake in Alberta, Canada, during the late 19th century to rich farm owners John and Elizabeth Howlett. However, James was actually the result of an extramarital affair between Elizabeth and the family's groundskeeper Thomas Logan. Thomas was also the father of Dog Logan, James's half-brother. Thomas became increasingly unstable because of his drinking, lost his job, and was expelled from the Howlett manor. He returned to the manor and killed John Howlett. In retaliation, James killed Thomas with bone claws that emerged from the back of his hands, as his mutation manifested. He fled with his childhood companion, Rose, and grew into manhood on a mining colony in Yukon, adopting the name "Logan". When Logan accidentally killed Rose with his claws, he fled the colony and lived in the wilderness among wolves. Logan then resided with the Blackfoot people. Sabretooth apparently killed Logan's Blackfoot lover, Silver Fox. Logan joined the Canadian military during World War I, and then became a career soldier. During World War II, Logan teamed up with Captain America. He spent time in Madripoor before settling in Japan, where he married a civilian, Itsu. While Logan was away from home, Romulus sent the Winter Soldier to kill the pregnant Itsu and had her baby taken from her womb. While Logan believed his son to be dead, the child was taken and given the name Daken. Wolverine later worked for the Central Intelligence Agency before being recruited by Team X, a black ops unit.
DNA methylation is a widespread mechanism for epigenetic influence on gene expression and is seen in bacteria and eukaryotes and has roles in heritable transcription silencing and transcription regulation. Methylation most often occurs on a cytosine (see Figure). Methylation of cytosine primarily occurs in dinucleotide sequences where a cytosine is followed by a guanine, a CpG site. The number of CpG sites in the human genome is about 28 million. Depending on the type of cell, about 70% of the CpG sites have a methylated cytosine. Methylation of cytosine in DNA has a major role in regulating gene expression. Methylation of CpGs in a promoter region of a gene usually represses gene transcription while methylation of CpGs in the body of a gene increases expression. TET enzymes play a central role in demethylation of methylated cytosines. Demethylation of CpGs in a gene promoter by TET enzyme activity increases transcription of the gene.
Pharmacologic or genetic removal of the Aβ in animal models of AD eliminates the disruption in normal mTOR activity, pointing to the direct involvement of Aβ in mTOR signaling. In addition, by injecting Aβ oligomers into the hippocampi of normal mice, mTOR hyperactivity is observed. Cognitive impairments characteristic of AD appear to be mediated by the phosphorylation of PRAS-40, which detaches from and allows for the mTOR hyperactivity when it is phosphorylated; inhibiting PRAS-40 phosphorylation prevents Aβ-induced mTOR hyperactivity. Given these findings, the mTOR signaling pathway appears to be one mechanism of Aβ-induced toxicity in AD. The hyperphosphorylation of tau proteins into neurofibrillary tangles is one hallmark of AD. p70S6K activation has been shown to promote tangle formation as well as mTOR hyperactivity through increased phosphorylation and reduced dephosphorylation. It has also been proposed that mTOR contributes to tau pathology by increasing the translation of tau and other proteins. Synaptic plasticity is a key contributor to learning and memory, two processes that are severely impaired in AD patients. Translational control, or the maintenance of protein homeostasis, has been shown to be essential for neural plasticity and is regulated by mTOR. Both protein over- and under-production via mTOR activity seem to contribute to impaired learning and memory.
Sources: en.wikipedia.org
=== Water purification === Graphite oxides were studied for desalination of water using reverse osmosis beginning in the 1960s. In 2011, additional results from research were published. In 2013, Lockheed Martin announced their Perforene graphene filter. Lockheed claims the filter reduces energy costs for reverse osmosis desalination by 99%. Lockheed claimed that the filter was 500 times thinner than the best filter on the market, 1,000 times stronger, and required 1% of the pressure. The product was not expected to be released until 2020. Another study showed that graphite oxide could be engineered to allow water to pass while retaining some larger ions. Narrow capillaries allow rapid permeation by mono- or bilayer water. Multilayer laminates have a structure similar to nacre, which provides mechanical strength in water-free conditions. Helium cannot pass through the membranes in humidity-free conditions, but penetrates easily when exposed to humidity, whereas water vapor passes with no resistance. Dry laminates are vacuum-tight, but immersed in water, they act as molecular sieves, blocking some solutes. A third project produced graphene sheets with subnanoscale (0.40 ± 0.24 nm) pores. The graphene was bombarded with gallium ions, which disrupt carbon bonds. Etching the result with an oxidizing solution produces a hole at each spot struck by a gallium ion. The length of time spent in the oxidizing solution determined the average pore size. Pore density reached 5 trillion pores per square centimeter, while retaining structural integrity.
of an antigen with additional information such as B and T-cell epitopes, MHC binding, function, gene-expression and post translational modifications, when available. AntigenDB also provides links to major internal and external databases. PolysacDB: A database dedicated to provide comprehensive information about antigenic polysaccharides of microbial origin (bacterial and fungal), antibodies against them, proposed epitopes, structural detail, proposed functions, assay system, cross-reactivity related information and more. It is a manually curated database where most of data has been collected from PubMed and PubMed Central literature databases. TumorHoPe: TumorHoPe is a manually curated comprehensive database of experimentally characterized tumor homing peptides. These peptides recognize tumor tissues and tumor associated micro environments, including tumor metastasis. ccPDB: A database designed to service researchers working in the field of function or structure annotation of proteins. This database of datasets is based on Protein Data Bank (PDB). OSDDchem: This chemical database is an open repository of information on synthesized, semi-synthesized, natural, and virtually designed molecules from the OSDD community. CancerDR: A database of 148 anticancer drugs and their effectiveness against around 1000 cancer cell lines. CancerDR maintains comprehensive information about these drugs, their target gene/protein, and cell lines.
== Publications == The ICHR publishes online as well as on print media. It publishes two journals: the Indian Historical Review (bi-annually) and Itihas (in Hindi). It also provides publication subsidies to seminars, books, congress proceedings, and journals. The editing and publication has been outsourced to certain publishing houses.
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.